Ipilimumab

Ipilimumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Diffuse Astrocytoma, IDH-Mutant、Glioblastoma, IDH-wildtype、Brain Metastases, Adult、Cervical Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Ipilimumab 研究

• Naltrexone and Propranolol Combined With Immunotherapy

  I 期招募中美国NCT05968690

• Timing of Immunotherapy in Melanoma

  不适用招募中荷兰NCT07696715

• rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

  I 期招募中美国NCT04943848

• A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国ChileIsrael日本NCT05584670

• Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

  II 期招募中美国NCT05361720

• VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

  II 期招募中美国NCT07510334

• JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors

  不适用招募中法国NCT04294771

• Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer

  II 期招募中中国NCT07867392

• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

  I 期 / II 期招募中美国NCT06362369

• Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.

  IV 期招募中意大利NCT06903312

• A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

  II 期招募中美国NCT05048212

• Towards Cure Via Only Ultra-short ICB in CSCC

  II 期招募中荷兰NCT06823479

• A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

  II 期招募中美国NCT07603856

• Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

  I 期 / II 期招募中比利时荷兰西班牙NCT04954599

• TDM for Optimized Outcome in Patients With mRCC.

  不适用招募中丹麦NCT04659343

• Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

  I 期招募中美国NCT04697576

• A 2-part Phase 1/2 Open-label Trial on ODM-212

  I 期 / II 期招募中美国丹麦芬兰法国NCT07563738

• Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

  II 期招募中美国NCT07155317

• SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety

  II 期招募中中国NCT07174947

• Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

  II 期招募中中国NCT06492421

• Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

  III 期招募中美国加拿大NCT07166406

• A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

  II 期 / III 期招募中美国NCT06624644

• Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

  II 期招募中美国NCT06295159

• Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)

  II 期招募中加拿大NCT05663775

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。